Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

RI-001

Plasma-derived product · Immune activation, directed at respiratory syncytial virus · developed by ADMA Biologics

Phase 2 Most advanced trial (none active)
ADMA Developer
1 Registered trials

What is RI-001?

RI-001 is a plasma-derived polyclonal intravenous immunoglobulin containing high-titer antibodies against respiratory syncytial virus (RSV). It provides passive immunization against RSV to prevent lower respiratory tract infections in immunocompromised patients.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Plasma-derived product
Targets
respiratory syncytial virus
Mechanism
Immune activation, directed at respiratory syncytial virus
Therapy area
Infectious disease
Developer
ADMA Biologics, Inc. (ADMA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00632463 Phase 2 Upper Respiratory Tract Infection Completed ADMA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lower Respiratory Tract InfectionUpper Respiratory Tract Infection

More from ADMA Biologics

immunoglobulin G FDA approved RI-002 FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ADMA page.

Follow ADMA, the company behind RI-001

See ADMA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ADMA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.